BCAL Diagnostics Limited (ASX:BDX)

Jayne Shaw
Chairman
Market Cap (AUD): 23.67M
Sector: Unclassified
Last Trade (AUD): 0.18 +0 (+0%)
Tab Bar

1. About

BCAL Diagnostics Limited (ASX:BDX) is developing a non-invasive laboratory blood test for the detection of breast cancer. 

The Company believes that early diagnosis of breast cancer and early intervention will improve clinical outcomes for all women. 

BCAL Diagnostics has a dedicated team of individuals aiming to deliver this test to all women. Since forming in 2010, the Company has been striving to address the issues surrounding the early detection and more accurate method of screening for breast cancer.

Current imaging technologies are effective in screening for the disease but have limitations. Biomarkers for breast cancer are ideal to overcome these issues, as they eliminate the need for imaging the breast. BCAL Diagnostics believes there is a need for more accurate screening for women of all ages, which can detect the cancer at a cellular level and before metastasis.

2. Business model

3. Strategy

4. Markets

5. Competition

6. History

7. Team

8. Financials

9. Risk